Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leisha A Emens

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Immunotherapy|September 9, 2016
Specific immunotherapy in ovarian cancer: a systematic reviewSoroush Aalipour, Samaneh Zoghi, Nastaran Khalili, et al.
Iscience|July 20, 2022
Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancerHanwen Wang, Chen Zhao, Cesar A Santa-Maria, et al.
Cancer Immunology Research|December 3, 2017
Report on the Third FDA-AACR Oncology Dose-Finding WorkshopLeisha A Emens, Rene Bruno, Eric H Rubin, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Advances and challenges in cancer immunoprevention and immune interceptionSasha E Stanton, Philip E Castle, Olivera J Finn, et al.
Science Advances|June 30, 2023
A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibitionTheinmozhi Arulraj, Hanwen Wang, Leisha A Emens, et al.
Cellular Immunology|March 30, 2010
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceLukas W Pfannenstiel, Samuel S K Lam, Leisha A Emens, et al.
Breast Cancer Research and Treatment|November 28, 2002
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancerLeisha A Emens, M John Kennedy, John H Fetting, et al.
The American Journal of Surgical Pathology|April 15, 2015
Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costsChristopher J VandenBussche, Ashley Cimino-Mathews, Ben Ho Park, et al.
Cancer Cell|August 18, 2023
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapySuzanne L Topalian, Patrick M Forde, Leisha A Emens, et al.
The American Journal of Surgical Pathology|June 15, 2016
Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/yChristopher J VandenBussche, Ashley Cimino-Mathews, Ben Ho Park, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Immunotherapy|September 9, 2016
Specific immunotherapy in ovarian cancer: a systematic reviewSoroush Aalipour, Samaneh Zoghi, Nastaran Khalili, et al.
Iscience|July 20, 2022
Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancerHanwen Wang, Chen Zhao, Cesar A Santa-Maria, et al.
Cancer Immunology Research|December 3, 2017
Report on the Third FDA-AACR Oncology Dose-Finding WorkshopLeisha A Emens, Rene Bruno, Eric H Rubin, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Advances and challenges in cancer immunoprevention and immune interceptionSasha E Stanton, Philip E Castle, Olivera J Finn, et al.
Science Advances|June 30, 2023
A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibitionTheinmozhi Arulraj, Hanwen Wang, Leisha A Emens, et al.
Cellular Immunology|March 30, 2010
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceLukas W Pfannenstiel, Samuel S K Lam, Leisha A Emens, et al.
Breast Cancer Research and Treatment|November 28, 2002
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancerLeisha A Emens, M John Kennedy, John H Fetting, et al.
The American Journal of Surgical Pathology|April 15, 2015
Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costsChristopher J VandenBussche, Ashley Cimino-Mathews, Ben Ho Park, et al.
Cancer Cell|August 18, 2023
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapySuzanne L Topalian, Patrick M Forde, Leisha A Emens, et al.
The American Journal of Surgical Pathology|June 15, 2016
Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/yChristopher J VandenBussche, Ashley Cimino-Mathews, Ben Ho Park, et al.
Pageof 12